Literature DB >> 1694724

Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6.

J B Wilson1, W Weinberg, R Johnson, S Yuspa, A J Levine.   

Abstract

The BNLF-1 gene of Epstein-Barr virus (EBV) encodes the latent membrane protein (LMP), one of the putative oncogene products of the virus. This gene has been expressed from two different enhancer-promoter constructs in transgenic mice, to determine its biological activity and possible contribution to oncogenesis. While transgenic mice expressing LMP in many tissues demonstrated poor viability, expression of LMP specifically in the epidermis induces a phenotype of hyperplastic dermatosis. Concomitant with the expression of LMP in this tissue (and in the esophagus) is an induction of the expression of a hyperproliferative keratin, K6, at aberrant locations within the epidermis. The epithelial hyperplastic phenotype caused by the LMP-encoding transgenes implies that the LMP plays a role in the acanthotic condition of the tongue epithelium in the human EBV- and HIV-associated syndrome oral hairy leukoplakia, as well as possibly predisposing the nasopharyngeal epithelium to carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1694724     DOI: 10.1016/0092-8674(90)90695-b

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  62 in total

1.  The murine gammaherpesvirus 68 v-cyclin gene is an oncogene that promotes cell cycle progression in primary lymphocytes.

Authors:  L F van Dyk; J L Hess; J D Katz; M Jacoby; S H Speck; I V Virgin HW
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases.

Authors:  Chi-Neu Tsai; Chia-Lung Tsai; Ka-Po Tse; Hwan-You Chang; Yu-Sun Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-10       Impact factor: 11.205

3.  Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity.

Authors:  M L Hammarskjöld; M C Simurda
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

4.  Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B-lymphoma cells.

Authors:  D Liebowitz; J Mannick; K Takada; E Kieff
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

5.  Induction of Epstein-Barr virus latent membrane protein 1 by a lytic transactivator Rta.

Authors:  Yao Chang; Heng-Huan Lee; Shih-Shin Chang; Tsuey-Ying Hsu; Pei-Wen Wang; Yu-Sun Chang; Kenzo Takada; Ching-Hwa Tsai
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

Review 6.  Molecular basis for Epstein-Barr virus induced pathogenesis and disease.

Authors:  C Sample; E Kieff
Journal:  Springer Semin Immunopathol       Date:  1991

7.  Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells.

Authors:  H Herbst; F Dallenbach; M Hummel; G Niedobitek; S Pileri; N Müller-Lantzsch; H Stein
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

8.  Epstein-Barr virus-encoded LMP1 regulates epithelial cell motility and invasion via the ERK-MAPK pathway.

Authors:  Christopher W Dawson; Louise Laverick; Mhairi A Morris; Giorgos Tramoutanis; Lawrence S Young
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

9.  Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein.

Authors:  K M Kaye; O Devergne; J N Harada; K M Izumi; R Yalamanchili; E Kieff; G Mosialos
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

Review 10.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Springer Semin Immunopathol       Date:  1998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.